Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $989K | $558K | $617K | $336K |
| Revenue growth | — | — | — | — | — | — | — | -43.6% | 10.7% | -45.5% |
| Operating income | -$24.5M | -$13.3M | -$8.05M | -$6.30M | -$4.96M | -$4.67M | -$3.43M | -$2.90M | -$4.53M | -$5.29M |
| Operating margin | — | — | — | — | — | — | -346.6% | -520.2% | -734.4% | -1575.3% |
| Net income | -$24.4M | -$13.5M | -$8.15M | -$6.92M | -$6.68M | -$5.54M | -$3.55M | -$3.10M | -$4.73M | -$5.43M |
| Net margin | — | — | — | — | — | — | -359.4% | -556.2% | -766.9% | -1615.8% |
| EPS (diluted) | -$0.12 | -$0.04 | -$0.02 | -$0.02 | -$0.02 | -$0.01 | -$0.01 | -$0.01 | -$0.01 | -$0.01 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$21.9M | -$10.3M | -$5.20M | -$6.19M | -$4.09M | -$1.01M | -$3.04M | -$2.57M | -$3.28M | -$3.33M |
| Capital expenditures | — | $30.4K | — | — | — | — | — | — | — | — |
| Free cash flow | — | -$10.4M | — | — | — | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.17M | $106K | $51.0K | $591K | $97.2K | $683K | $21.6K | $76.6K | $307K | $251K |
| Total assets | $5.61M | $3.44M | $1.99M | $1.48M | $589K | $3.51M | $2.04M | $1.45M | $1.01M | $698K |
| Total liabilities | $2.14M | $13.5M | $19.4M | $25.5M | $30.8M | $7.70M | $8.27M | $9.04M | $6.98M | $7.00M |
| Shareholders' equity | $3.47M | -$10.0M | -$17.4M | -$24.1M | -$30.2M | -$4.19M | -$6.23M | -$7.59M | -$5.96M | -$6.30M |
| Retained earnings | -$205M | -$219M | -$227M | -$234M | -$240M | -$246M | -$250M | -$253M | -$257M | -$263M |
| Shares (wtd avg diluted) | 365M | 371M | 385M | 390M | 399M | 408M | 419M | 420M | 420M | 420M |
Every figure is extracted from PROVECTUS BIOPHARMACEUTICALS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.